Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

4.485 -0.145 (-3.13%)
Streaming Delayed Price Updated: 2:06 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
From ADC Therapeutics SA
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
Earnings Preview: ADC Therapeutics
 
Via Benzinga
The Latest Analyst Ratings for ADC Therapeutics
 
Via Benzinga
4 Analysts Have This to Say About ADC Therapeutics
 
Via Benzinga
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
From ADC Therapeutics SA
Via Business Wire
Analyst Ratings for ADC Therapeutics
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: 
Via Benzinga
ADC Therapeutics to Participate in February Investor Conferences
From ADC Therapeutics SA
Via Business Wire
Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity... 
Via Benzinga
TSMC, CommScope Holding And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
From ADC Therapeutics SA
Via Business Wire
Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday 
Via InvestorPlace
Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket
Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed... 
Via Benzinga
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
From ADC Therapeutics SA
Via Business Wire
Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal
Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built... 
Via Talk Markets
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
From ADC Therapeutics SA
Via Business Wire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
From ADC Therapeutics SA
Via Business Wire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
From IGM Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.